Authorization

The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More

The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More
Biotech stocks alternated between gains and losses in the week ended Jan. 29 before ending lower. Big pharma earnings season kick started, with Novartis AG(NYSE:NVS), Johnson & Johnson (NYSE:JNJ) and Eli Lilly And Co (NYSE:LLY) all in the mix.

Coronavirus vaccine and treatment news flow abounded in the week. J&J and Novavax, Inc. (NASDAQ:NVAX) released top-line results from their respective late-stage vaccine studies. Merck & Co., Inc. (NYSE:MRK), meanwhile, dropped out of the vaccine race.

Lilly and Vir Biotechnology Inc (NASDAQ:VIR) announced a study combining their COVID-19 antibody treatments.

Biogen Inc (NASDAQ:BIIB) reacted with a move to the upside after the Food and Drug Administration extended the review period of its Alzheimer's drug, aducanumab, by three months.

Here are the key catalytic events for the unfolding week:
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Декабрь 2021    »
ПнВтСрЧтПтСбВс
 12345
6789101112
13141516171819
20212223242526
2728293031